
MRUS
Healthcare · Biotechnology · $6.83B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now · +17.0% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 13, 2026 | Time not confirmed | -1.35 | 0.00 | +100.0% |
| Mar 4, 2026 | Time not confirmed | -1.14 | 0.00 | +100.0% |
| Oct 30, 2025 | Time not confirmed | -1.38 | -1.26 | +8.7% |
| Jul 30, 2025 | After the close | -1.14 | -2.23 | -95.6% |
| May 6, 2025 | Before the open | -1.06 | -1.40 | -31.6% |
| Feb 26, 2025 | Before the open | -0.90 | -0.49 | +45.7% |
| Oct 31, 2024 | Before the open | -0.88 | -1.46 | -65.9% |
| Aug 1, 2024 | After the close | -0.76 | -0.81 | -6.6% |
| May 8, 2024 | After the close | -0.81 | -0.59 | +27.2% |
| Feb 28, 2024 | After the close | -0.74 | -1.04 | -40.5% |
| Nov 2, 2023 | After the close | -0.73 | -0.43 | +41.1% |
| Aug 7, 2023 | After the close | -0.88 | -0.66 | +25.0% |
| May 4, 2023 | After the close | -1.02 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of…
| -0.86 |
| +15.7% |
| Feb 28, 2023 | After the close | -0.83 | -1.81 | -118.1% |
| Nov 3, 2022 | Before the open | -0.63 | -0.53 | +15.9% |
| Aug 8, 2022 | After the close | -0.62 | -0.13 | +79.0% |
| May 9, 2022 | After the close | -0.62 | -0.43 | +30.6% |
| Feb 28, 2022 | After the close | -0.62 | -0.34 | +45.2% |
| Nov 2, 2021 | After the close | -0.62 | -0.39 | +37.1% |
| Aug 5, 2021 | After the close | -0.59 | -0.71 | -20.3% |
| May 6, 2021 | After the close | -0.24 | -0.28 | -16.7% |
| Mar 16, 2021 | After the close | -0.63 | -1.06 | -68.3% |
| Nov 5, 2020 | After the close | -0.56 | -0.64 | -14.3% |
| Aug 6, 2020 | After the close | -0.61 | -0.54 | +11.5% |
| May 11, 2020 | After the close | -0.53 | -0.62 | -17.0% |
| Mar 12, 2020 | After the close | -0.46 | -0.92 | -100.0% |
| Nov 12, 2019 | After the close | -0.49 | -0.35 | +28.6% |
| Aug 19, 2019 | After the close | -0.48 | -0.51 | -6.3% |
| May 30, 2019 | After the close | -0.52 | -0.26 | +50.0% |
| Dec 31, 2018 | Time not confirmed | -0.74 | -0.02 | +97.3% |
| Dec 27, 2018 | After the close | -0.62 | -0.47 | +24.2% |
| Jul 26, 2018 | Before the open | -0.75 | -0.40 | +46.7% |
| Apr 26, 2018 | Before the open | -0.62 | -0.73 | -17.7% |